Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis

BACKGROUND: Pembrolizumab and cemiplimab have been approved as treatment for advanced non-small-cell lung cancer (NSCLC) with high programmed death ligand-1 (PD-L1) expression. This study aimed to evaluate the cost-effectiveness of pembrolizumab compared with that of cemiplimab in the treatment of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Liang, Xueyan, Yang, Tong, Guo, Sitong, Chen, Xiaoyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549171/
https://www.ncbi.nlm.nih.gov/pubmed/36226060
http://dx.doi.org/10.3389/fonc.2022.878054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549171/
https://www.ncbi.nlm.nih.gov/pubmed/36226060
http://dx.doi.org/10.3389/fonc.2022.878054

Ejemplares similares